List view / Grid view

Downstream

 

article

Rapid method development to overcome challenges of bi-specific antibody purification

27 June 2022 | By ,

The landscape of biopharmaceutical manufacturing is changing, with complex molecules such as bi-specific antibodies (bsAbs) becoming increasingly prevalent. bsAbs are a large, structurally diverse family of molecules designed to recognise two targets and globally there are over 230 in development as promising therapies for cancer and other diseases. While they…

article

Overview of workflows and data approaches in bioproduction – an industry perspective

28 August 2020 | By

Downstream processing is an integral part of the production process of biopharmaceuticals and contributes quite significantly to the overall productivity and product quality, as well as to processing costs. Melanie Diefenbacher of Genedata provides a comprehensive overview of downstream processes, highlighting several challenges and the importance of investing into automation…

webinar

The analytical reality of recombinant endotoxin technologies

29 July 2020 | By Charles River

In this webinar we discuss the results of our latest study where we evaluated the ruggedness, repeatability and specificity of commercially available rFC products, as well as our own recombinant product in development, against a large panel of endotoxins.

webinar

A 360 overview of data integrity in life sciences

7 February 2020 | By OSIsoft

Trustworthiness in data is critical for operations within the pharmaceutical and life sciences industries, whether it is for compliance, operational excellence, reporting or development. Hear the latest findings from OSIsoft’s research in our on-demand webinar.

article

Regulatory non-compliance business interruptions

29 October 2019 | By

Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.